ONWD (ONWD) News
Follow ONWD (ONWD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
ONWARD Medical Reports €2.5M in Q3 2026 Revenue
The company reported €2.0M of revenue from ARC-EX systems. Cash was €73.4M at September 30, and ONWARD drew €20M under a financing agreement for up to €50M.
EQUITY | Nov 03, 2026, 06:32 AM UTC
M
ONWD 1H 2026 revenue rises 250% YoY to €4.2M
ONWD reported 1H 2026 revenue up 250% year-over-year to €4.2M, citing strong ARCEX commercial uptake and pipeline progress. Cash balance reached €81.5M after raising over €40M in equity and securing a new €50M debt facil
EQUITY | Sep 09, 2026, 05:23 PM UTC
M
Onward Medical revenue jumps 250% YoY to EUR 4.2 million
Onward Medical reports revenue up 250% year-over-year to EUR 4.2 million, driven by ARC-EX adoption in the U.S. and Europe. Cash position strengthened to EUR 81.5 million.
CENTRAL_BANK | Sep 09, 2026, 02:05 PM UTC
M
Onward Medical ARC-EX sales surge 5x; cash rises to EUR 81.5m
ARC-EX sales increased 5x year-over-year, with a 250% revenue increase. Cash strengthened to EUR 81.5 million, supporting pivotal trials and commercialization. Interim Empower BP results expected in early 2027.
EQUITY | Sep 09, 2026, 01:34 PM UTC
L
ONWARD Medical Reports First Half 2026 Results with Strong Product Revenue Growth and Continued Progress across ARC Therapy Pipeline
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)EINDHOVEN, the Netherlands, Sept. 09, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euro
REGULATION | Sep 09, 2026, 05:37 AM UTC
L
Onward Medical revenue quadruples to €4.2M; €40M raise boosts liquidity
Revenue and other income quadrupled year-over-year to €4.2M, driven by ARCEX commercialization and new market expansion. Net loss widened to €24.7M. A €40M capital raise and new debt facility strengthened liquidity and e
EARNINGS | Sep 09, 2026, 05:34 AM UTC
L
Onward Medical revenue jumps 240% YoY on ARC-EX unit surge
Onward Medical N.V. reports revenue up 240% year-over-year, driven by a 430% increase in ARC-EX units and expanded home-use access.
EARNINGS | Sep 09, 2026, 05:33 AM UTC
L
Onward Opportunities reports NAV of 123.5p per share at 30 June 2026
Onward Opportunities Ltd says its NAV is 123.5p per share as at 30 June 2026.
EQUITY | Sep 08, 2026, 06:37 AM UTC
L
Onward Opportunities posts half-year financial report
Onward Opportunities Limited released a half-year financial report, with the company stating the announcement contains inside information under Article 7 of EU Regulation 596/2014 (as UK domestic law).
EQUITY | Sep 08, 2026, 06:00 AM UTC
L
Onward Medical to announce first-half 2026 results September 9, 2026
ONWARD Medical N.V. said it will announce first-half 2026 results on September 9, 2026.
EQUITY | Sep 04, 2026, 05:38 AM UTC
L
ONWARD Medical announces first implant in ARC-IM clinical feasibility study
ONWARD Medical N.V. said it has announced the first implant in the EIGER clinical feasibility study evaluating its ARC-IM system to restore mobility after spinal cord injury.
EQUITY | Sep 03, 2026, 05:37 AM UTC
L
Onward Opportunities fund passes £50m; NAV hits record high
RCS - Onward Opportunities fund passed £50m. NAV reached a record high.
EQUITY | Sep 01, 2026, 06:01 AM UTC